FDA — authorised 24 July 2023
- Marketing authorisation holder: TARSUS
- Status: approved
🇺🇸 Xdemvy in United States
FDA authorised Xdemvy on 24 July 2023
Marketing authorisations
FDA — authorised 24 July 2023
- Application: NDA217603
- Marketing authorisation holder: TARSUS
- Local brand name: XDEMVY
- Indication: SOLUTION/DROPS — OPHTHALMIC
- Status: approved
Xdemvy in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in United States
Frequently asked questions
Is Xdemvy approved in United States?
Yes. FDA authorised it on 24 July 2023; FDA authorised it on 24 July 2023.
Who is the marketing authorisation holder for Xdemvy in United States?
TARSUS holds the US marketing authorisation.